Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The Knee
NCT ID: NCT00120900
Last Updated: 2017-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1340 participants
INTERVENTIONAL
2005-05-31
2007-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis
NCT03595618
A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain
NCT05838742
A Study of GW842166 in Adults With Osteoarthritis Pain
NCT00447486
Efficacy and Safety of G001 in Patients With Osteoarthritis (OA) of the Knee
NCT05007808
A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)
NCT03485365
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GW406381
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Use pain medication, such as a COX-2 inhibitor or NSAID (non-steroidal anti-inflammatory drug) at least 5 days per week.
Exclusion Criteria
* History of gastroduodenal perforations and/or obstructions.
* History of upper GI (gastrointestinal) ulceration within the previous 6 months.
* History of upper or lower GI bleeding within the previous year.
* History of inflammatory bowel disease.
* Currently take sucralfate or misoprostol.
* Currently taking aspirin daily for the heart.
* Other restrictions around the use medications apply and would need to be discussed.
* History of coronary artery disease, (angina, MI) or surgery.
* History of congestive heart failure or renal artery stenosis.
* History of stroke or transient ischemic attack.
* History of uncontrolled hypertension.
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Ishøj, , Denmark
GSK Investigational Site
De Bilt, , Netherlands
GSK Investigational Site
Ewijk, , Netherlands
GSK Investigational Site
Heerlen, , Netherlands
GSK Investigational Site
Bergen, , Norway
GSK Investigational Site
Hamar, , Norway
GSK Investigational Site
Hønefoss, , Norway
GSK Investigational Site
Lier, , Norway
GSK Investigational Site
Oslo, , Norway
GSK Investigational Site
Anyang-si, , South Korea
GSK Investigational Site
Daegu, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
San Juan, , Spain
GSK Investigational Site
Helsingborg, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CXA30007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.